ComiGDe StefanoNFreedmanMS. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol2012; 11: 33–41.
2.
ComiGFilippiMBarkhofF. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001; 357: 1576–1582.
3.
KapposLPolmanCHFreedmanMS. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006; 67: 1242–1249.
4.
ComiGMartinelliVRodegherM. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet2009; 374: 1503–1511.
5.
JacobsLDBeckRWSimonJH. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med2000; 343: 898–904.
6.
FisnikuLKBrexPAAltmannDR. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
